Literature DB >> 23286449

Association between Osteopontin and EGFR Expression with Clinicopathological Parameters in Hepatocellular Carcinoma.

Wen-Chiuan Tsai1, Wen-Chiuan Tsai1, Herng-Sheng Lee, Jong-Shiaw Jin, Hong-Wei Gao, Tai-Kuang Chao, Ann Chen, Shi Nieh, De-Chuan Chan, Fei-Ni Chang, Chih-Kung Lin.   

Abstract

Osteopontin (OPN) and epidermal growth factor receptor (EGFR) are important factors associated with tumor progression, invasion and metastasis in humans. The aim of this study was to assess the correlation of OPN and EGFR expression with hepatocellular carcinoma (HCC) progression. Expression of OPN and EGFR was assessed by immunohistochemistry in 100 HCC specimens. Immunostaining scores (0 to 400) were calculated from the percentage of cells (0 to 100) at each immunostaining intensity and the immunostaining intensity (0 to 4). The average immunostaining score for OPN was correlated with tumor grade (56.1 for grade I, 104.6 for grade II, and 141.2 for grade III; P = 0.023) and T stage (58.6 for stage T1, 85.9 for stage T2, 126.8 for stage T3, and 189.1 for stage T4; P = 0.029). Similarly, the average immunostaining score for EGFR was correlated with tumor grade (80.5 for grade I, 142.1 for grade II, 230.6 for grade III; P = 0.011) and T stage (96.4 for stage T1, 135.5 for stage T2, 221.3 for stage T3, and 261.4 for stage T4; P = 0.026). In addition, OPN and EGFR immunostaining scores were also correlated with M, N, and AJCC stages. In conclusion, higher expression of OPN and EGFR is significantly associated with advanced histological grades, advanced pathological stages and poorer survival rates in HCC. OPN and EGFR may be used as novel biomarkers for diagnosis or monitoring of progression of hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23286449     DOI: 10.4077/CJP.2012.BAA082

Source DB:  PubMed          Journal:  Chin J Physiol        ISSN: 0304-4920            Impact factor:   1.764


  8 in total

Review 1.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

2.  Osteopontin promoter polymorphisms at locus -443 are associated with metastasis and poor prognosis of human intrahepatic cholangiocarcinoma in Chinese population.

Authors:  Xiang-Qian Zhao; Huan-Xian Ma; Mao-Sheng Su; Lei He
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 3.  Active radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems.

Authors:  Jing-Jun Yan; Jia-Zhi Liao; Ju-Sheng Lin; Xing-Xing He
Journal:  Tumour Biol       Date:  2014-11-26

4.  Genome-wide association study identified PLCE1- rs2797992 and EGFR- rs6950826 were associated with TP53 expression in the HBV-related hepatocellular carcinoma of Chinese patients in Guangxi.

Authors:  Xiwen Liao; Chuangye Han; Wei Qin; Xiaoguang Liu; Long Yu; Sicong Lu; Zhiwei Chen; Guangzhi Zhu; Hao Su; Zengnan Mo; Xue Qin; Tao Peng
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

5.  Suppression of osteopontin inhibits chemically induced hepatic carcinogenesis by induction of apoptosis in mice.

Authors:  Su-Hyung Lee; Jun-Won Park; Sang-Ho Woo; Du-Min Go; Hyo-Jung Kwon; Ja-June Jang; Dae-Yong Kim
Journal:  Oncotarget       Date:  2016-12-27

Review 6.  Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Tingting Sun; Peng Li; Diwen Sun; Qingao Bu; Guoqiang Li
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

7.  Chenodeoxycholic Acid Enhances the Effect of Sorafenib in Inhibiting HepG2 Cell Growth Through EGFR/Stat3 Pathway.

Authors:  Yang Zhang; Yan Zhang; Xiao-Jun Shi; Jun-Xiang Li; Lin-Heng Wang; Chun-E Xie; Yun-Liang Wang
Journal:  Front Oncol       Date:  2022-02-17       Impact factor: 6.244

8.  EGFR and SYNE2 are associated with p21 expression and SYNE2 variants predict post-operative clinical outcomes in HBV-related hepatocellular carcinoma.

Authors:  Chuangye Han; Xiwen Liao; Wei Qin; Long Yu; Xiaoguang Liu; Gang Chen; Zhengtao Liu; Sicong Lu; Zhiwei Chen; Hao Su; Guangzhi Zhu; Zili Lu; Zhiming Liu; Xue Qin; Ying Gui; Zengnan Mo; Lequn Li; Tao Peng
Journal:  Sci Rep       Date:  2016-08-09       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.